Wednesday, 07 December 2022


XJTLU, University of Liverpool open joint centre for pharmacology & therapeutics in China

10 November 2022 | News

The Joint Centre's research and development activities are expected to benefit both Suzhou – which boasts over 400 high-tech biopharmaceutical startups in its BioBAY industrial park and aims to be the "Pharmacy Valley of China" – and the Liverpool City Region

Image credit: prnewswire

Image credit: prnewswire

Xi'an Jiaotong-Liverpool University (XJTLU) and the University of Liverpool are opening a Joint Centre for Pharmacology and Therapeutics in China. 

The Joint Centre, a Sino-UK collaborative venture, will engage top scientists from both countries to enhance research on disease mechanisms and develop novel drugs for the treatment of modern-day diseases.

As a global research hub for interdisciplinary and innovative research, the Joint Centre will offer a unique platform for knowledge exchange and talent cultivation between academic laboratories and their industrial and clinical partners in basic and clinical research on drug safety science, immuno-pharmacology, precision medicine, nanomedicine and regulatory science.

Members of the Joint Centre include senior researchers from XJTLU; the Department of Pharmacology and Therapeutics from the University of Liverpool, an established world leader in pharmacology and toxicology research; Hengrui Pharmaceutical Co. (Shanghai), a pharmaceutical giant in China; and Suzhou Guangji Psychiatric Hospital.

The Joint Centre will harness state-of-the-art equipment and facilities in pharmaceutical sciences, molecular biology, chemistry, and environmental sciences along with activities funded by the government, the private sector and the pharmaceutical industry.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account